SymBio Pharmaceuticals: Summary of Consolidated Financial Statements for the First Six Months of the Fiscal Year Ending on December 31, 2024 [Japan GAAP]
SymBio Pharmaceuticals: Pennsylvania State University's School of Medicine has announced research findings that the antiviral drug brincidofovir suppresses the production of infectious viruses in the polyomavirus.
SymBio Pharmaceuticals: Confirmed antitumor effect of brentuximab vedotin on peripheral T-cell lymphoma (PTCL), inducing suppression of oncogene MYC and expression of immune regulatory genes.
SymBio Pharmaceuticals: FPI (the first case) was achieved in the phase 2a clinical trial of the injection brincidofovir targeting patients with cytomegalovirus infection after hematopoietic stem cell transplantation.
SymBio Pharmaceuticals: Notice Concerning Appointment of Executive Officers
SymBio Pharmaceuticals: Notice of commencement of clinical trials targeting cytomegalovirus infection after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA trial) with the injectable brincidofovir
SymBio Pharmaceuticals: Revision of the 2024 earnings forecast
SymBio Pharmaceuticals: Summary of consolidated financial statements for the first three months of the fiscal year ending December 31, 2024 [Japanese Standards]
SymBio Pharmaceuticals: Share Transfer Report Relating to Third-Party Allocation (New Shares)
SymBio Pharmaceuticals: Stock Transfer Report Affirmations Related to Third-Party Allocation (New Shares)
SymBio Pharmaceuticals: Onconova and Trawsfynydd Therapeutics, Inc. of the United States announce business integration and establishment of Traws Pharma, Inc.
SymBio Pharmaceuticals: Share Transfer Report Relating to Third-Party Allocation (New Shares)
SymBio Pharmaceuticals: Notice regarding personnel changes at the US subsidiary SymBio Pharma USA
Synbio Pharmaceuticals: Matters relating to business plans and growth potential
SymBio Pharmaceuticals: Notice regarding the aggregated results of the exercise of voting rights at the 19th Annual General Meeting of Shareholders
SymBio Pharmaceuticals: Notice of acquisition of brincidofovir orphan drug designation in the EU
SymBio Pharmaceuticals: Notice regarding the election of directors and executive officers
SymBio Pharmaceuticals: Antitumor effects of brincidofovir on B-cell lymphoma: conference presentation of research results at AACR Annual Meeting 2024
SymBio Pharmaceuticals: Stock Transfer Report Affirmations Related to Third-Party Allocation (New Shares)
Synbio Pharmaceuticals: Stock Transfer Report Relating to Third-Party Allotment (New Shares)
No Data